These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35717581)

  • 41. Exploring antiviral and anti-inflammatory effects of thiol drugs in COVID-19.
    Khanna K; Raymond WW; Jin J; Charbit AR; Gitlin I; Tang M; Werts AD; Barrett EG; Cox JM; Birch SM; Martinelli R; Sperber HS; Franz S; Duff T; Hoffmann M; Healy AM; Oscarson S; Pöhlmann S; Pillai SK; Simmons G; Fahy JV
    Am J Physiol Lung Cell Mol Physiol; 2022 Sep; 323(3):L372-L389. PubMed ID: 35762590
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.
    Miura Y; Ohkubo H; Nakano A; Bourke JE; Kanazawa S
    Front Immunol; 2022; 13():1028613. PubMed ID: 36405683
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
    Gupta VK; Murthy MK; Patil S
    Curr Drug Targets; 2021; 22(10):1149-1157. PubMed ID: 33243116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
    Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
    J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy.
    Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM
    Viruses; 2022 May; 14(5):. PubMed ID: 35632769
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Fenofibrate for COVID-19 and related complications as an approach to improve treatment outcomes: the missed key for Holy Grail.
    Alkhayyat SS; Al-Kuraishy HM; Al-Gareeb AI; El-Bouseary MM; AboKamer AM; Batiha GE; Simal-Gandara J
    Inflamm Res; 2022 Nov; 71(10-11):1159-1167. PubMed ID: 35941297
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ACE2, the kidney and the emergence of COVID-19 two decades after ACE2 discovery.
    Lores E; Wysocki J; Batlle D
    Clin Sci (Lond); 2020 Nov; 134(21):2791-2805. PubMed ID: 33135725
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Implications of SARS-CoV-2 Interaction With Renin Angiotensin System: JACC Review Topic of the Week.
    Brojakowska A; Narula J; Shimony R; Bander J
    J Am Coll Cardiol; 2020 Jun; 75(24):3085-3095. PubMed ID: 32305401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Renin-Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome.
    Hrenak J; Simko F
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage.
    Kirtipal N; Kumar S; Dubey SK; Dwivedi VD; Gireesh Babu K; Malý P; Bharadwaj S
    Infect Genet Evol; 2022 Apr; 99():105254. PubMed ID: 35217145
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential COVID-19 therapeutic approaches targeting angiotensin-converting enzyme 2; An updated review.
    Zanganeh S; Goodarzi N; Doroudian M; Movahed E
    Rev Med Virol; 2022 Jul; 32(4):e2321. PubMed ID: 34958163
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Structural and functional modelling of SARS-CoV-2 entry in animal models.
    Brooke GN; Prischi F
    Sci Rep; 2020 Sep; 10(1):15917. PubMed ID: 32985513
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinctive Roles of Furin and TMPRSS2 in SARS-CoV-2 Infectivity.
    Essalmani R; Jain J; Susan-Resiga D; Andréo U; Evagelidis A; Derbali RM; Huynh DN; Dallaire F; Laporte M; Delpal A; Sutto-Ortiz P; Coutard B; Mapa C; Wilcoxen K; Decroly E; Nq Pham T; Cohen ÉA; Seidah NG
    J Virol; 2022 Apr; 96(8):e0012822. PubMed ID: 35343766
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.
    Sarzani R; Giulietti F; Di Pentima C; Giordano P; Spannella F
    Am J Physiol Lung Cell Mol Physiol; 2020 Aug; 319(2):L325-L336. PubMed ID: 32639866
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
    Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
    Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activation of SARS-CoV-2 by trypsin-like proteases in the clinical specimens of patients with COVID-19.
    Yamazaki E; Yazawa S; Shimada T; Tamura K; Saga Y; Itamochi M; Inasaki N; Hasegawa S; Morinaga Y; Oishi K; Tani H
    Sci Rep; 2023 Jul; 13(1):11632. PubMed ID: 37468582
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sars-Cov2 Induced Biochemical Mechanisms in Liver Damage and Intestinal Lesions.
    Spirina LV; Masunov VN; Dyakov DA; Akbasheva OE; Kebekbayeva AY; Shuvalov IY; Masunova NV; Kovaleva IV; Dagbaeva Y
    Indian J Clin Biochem; 2022 Nov; 38(4):1-10. PubMed ID: 36407686
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protease-anti-protease compartmentalization in SARS-CoV-2 ARDS: Therapeutic implications.
    McElvaney OF; Asakura T; Meinig SL; Torres-Castillo JL; Hagan RS; Gabillard-Lefort C; Murphy MP; Thorne LB; Borczuk A; Reeves EP; Zumwalt RE; Mikami Y; Carroll TP; Okuda K; Hogan G; McElvaney OJ; Clarke J; McEvoy NL; Mallon PW; McCarthy C; Curley G; Wolfgang MC; Boucher RC; McElvaney NG
    EBioMedicine; 2022 Mar; 77():103894. PubMed ID: 35217407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessing the efficacy of Alpha
    Pierce LR
    Heliyon; 2024 Jun; 10(11):e31183. PubMed ID: 38912501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.